Neurocrine Biosciences reported $-23300000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.57M 79M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Aptinyx Inc APTX:US $ -17667000 2.16M
Biogen BIIB:US $ 874.8M 28.6M
Biomarin Pharmaceutical BMRN:US $ 34.85M 8.66M
Cytokinetics CYTK:US $ -19.82M 66.93M
Dynavax Technologies DVAX:US $ 129.37M 96.52M
Enanta Pharmaceuticals ENTA:US $ -32.15M 1.44M
Exelixis EXEL:US $ 88.51M 3.28M
Halozyme Therapeutics HALO:US $ 30.01M 51.62M
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
IONIS PHARMACEUT IONS:US $ -103M 39M
Nektar Therapeutics NKTR:US $ -158.97M 68.7M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Prothena PRTA:US $ -42.57M 4.61M
Rigel Pharmaceuticals RIGL:US $ -13.49M 13.95M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Teva Pharmaceutical TEVA:IT -1160000000 189M
Ultragenyx Pharmaceutical RARE:US $ -157.86M 6.1M
Xoma XOMA:US $ -4.67M 2.39M